Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

Carlo Maria Maria Bellanca,Egle Augello,Alice Mariottini,Gabriele Bonaventura,Valentina La Cognata,Giulia Di Benedetto,Anna Flavia Cantone,Giuseppe Attaguile,Rosaria Di Mauro,Giuseppina Cantarella,Luca Massacesi,Renato Bernardini

DOI: https://doi.org/10.2174/1570159x22666240124114126

2024-01-30

Current Neuropharmacology

Abstract:Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth decades of life. Usually, the clinical course is characterized by the involvement of multiple CNS functional systems and by different, often overlapping phenotypes. In the last decades, remarkable results have been achieved in the treatment of MS, particularly in the relapsing- remitting (RRMS) form, thus improving the long-term outcome for many patients. As deeper knowledge of MS pathogenesis and respective molecular targets keeps growing, nowadays, several lines of disease-modifying treatments (DMT) are available, an impressive change compared to the relative poverty of options available in the past. Current MS management by DMTs is aimed at reducing relapse frequency, ameliorating symptoms, and preventing clinical disability and progression. Notwithstanding the relevant increase in pharmacological options for the management of RRMS, research is now increasingly pointing to identify new molecules with high efficacy, particularly in progressive forms. Hence, future efforts should be concentrated on achieving a more extensive, if not exhaustive, understanding of the pathogenetic mechanisms underlying this phase of the disease in order to characterize novel molecules for therapeutic intervention. The purpose of this review is to provide a compact overview of the numerous currently approved treatments and future innovative approaches, including neuroprotective treatments as anti-LINGO-1 monoclonal antibody and cell therapies, for effective and safe management of MS, potentially leading to a cure for this disease.

pharmacology & pharmacy,neurosciences